Related Experiment Video
Updated: Jun 25, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Update on the therapy for myelodysplastic syndrome
Margaret T Kasner1, Selina M Luger
1Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. margaret.kasner@uphs.upenn.edu
Abstract:
The myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic stem cell disorders characterized by cytopenias. Patients have a risk of developing acute leukemia though most succumb to complications of low blood counts. Over the past decade many novel treatments have been developed and investigation of new agents is ongoing. In this article, we discuss the classification and prognostic systems that are used in MDS, the agents available for treatment of MDS as well as review supportive and palliative care options for patients who are not candidates for, or opt against, newer treatment strategies.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
iPS Cell Differentiation
